- Home
- BSII vs ACRV Comparison
BSII vs ACRV Comparison
Compare BSII & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSII
- ACRV
- Stock Information
- Founded
- BSII 2024
- ACRV 2018
- Country
- BSII Hong Kong
- ACRV United States
- Employees
- BSII N/A
- ACRV N/A
- Industry
- BSII
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- BSII
- ACRV Health Care
- Exchange
- BSII Nasdaq
- ACRV Nasdaq
- Market Cap
- BSII 189.1M
- ACRV 203.9M
- IPO Year
- BSII 2024
- ACRV 2022
- Fundamental
- Price
- BSII $9.93
- ACRV $6.60
- Analyst Decision
- BSII
- ACRV Strong Buy
- Analyst Count
- BSII 0
- ACRV 5
- Target Price
- BSII N/A
- ACRV $22.40
- AVG Volume (30 Days)
- BSII 24.3K
- ACRV 63.5K
- Earning Date
- BSII 01-01-0001
- ACRV 11-13-2024
- Dividend Yield
- BSII N/A
- ACRV N/A
- EPS Growth
- BSII N/A
- ACRV N/A
- EPS
- BSII N/A
- ACRV N/A
- Revenue
- BSII N/A
- ACRV N/A
- Revenue This Year
- BSII N/A
- ACRV N/A
- Revenue Next Year
- BSII N/A
- ACRV N/A
- P/E Ratio
- BSII N/A
- ACRV N/A
- Revenue Growth
- BSII N/A
- ACRV N/A
- 52 Week Low
- BSII $9.86
- ACRV $3.19
- 52 Week High
- BSII $10.30
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- BSII N/A
- ACRV 42.20
- Support Level
- BSII N/A
- ACRV $6.56
- Resistance Level
- BSII N/A
- ACRV $7.45
- Average True Range (ATR)
- BSII 0.00
- ACRV 0.47
- MACD
- BSII 0.00
- ACRV -0.00
- Stochastic Oscillator
- BSII 0.00
- ACRV 28.12
About BSII Black Spade Acquisition II Co Class A Ordinary Share
Black Spade Acquisition II Co is a blank check company.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.